Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

MIVI Neuroscience Expands European Commercialization Network After Achieving CE Mark Approval Of The R4Q Revascularization Catheter For Ischemic Stroke

MIVI Neuroscience
Posted on: 01 Jul 18
MIVI Neuroscience Expands European Commercialization Network After Achieving CE Mark Approval Of The R4Q Revascularization Catheter For Ischemic Stroke

PR Newswire

EDEN PRAIRIE, Minn., July 1, 2018

EDEN PRAIRIE, Minn., July 1, 2018 /PRNewswire/ -- MIVI Neuroscience, Inc. announced today the expansion of its European commercialization network with the commitment from AngioNautix of Madrid, Spain, to be its partner in Spain, Portugal and Cuba.  CE Mark approval for the R4Q Revascularization Catheter was received in March, and MIVI has now created a network of experienced and successful distribution partners to execute the focused launch of the R4Q System's suite of devices designed for the treatment of ischemic stroke.   

AngioNautix joins Neurologic Europe Ltd. in the United Kingdom, and Med-Italia Biomedica, S.r.l. in Italy as MIVI's partners.  Each organizations is a fully integrated industry leader in the neurovascular space with significant experience in launching novel, patient focused technologies. 

"We are very excited to add AngioNautix to the team at MIVI," said Jim McCollum, MIVI's CEO.  "We believe our partners will be effective in delivering our complete suite of products - including our family of Mi-Axus Guide Catheters and now the R4Q Revascularization System - to their unique interventional neurovascular communities."

About MIVI Neuroscience

MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures.  Adoption of endovascular stroke therapy procedures is growing significantly worldwide since compelling data from multiple large-scale randomized trials in 2016 and 2017 confirmed the value to rapidly clear occlusive clot from large cerebral vessels. MIVI's innovative product portfolio provides physicians with unique devices designed to improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients.  More information about MIVI can be found on the website, www.mivineuro.com.

 

View original content:http://www.prnewswire.com/news-releases/mivi-neuroscience-expands-european-commercialization-network-after-achieving-ce-mark-approval-of-the-r4q-revascularization-catheter-for-ischemic-stroke-300675098.html

SOURCE MIVI Neuroscience

PR Newswire
www.prnewswire.com

Last updated on: 01/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.